oral glp 1 agonist for type 2 diabetes A Review on Semaglutide: An Glucagon-Like Peptide Receptor in Management of Mellitus | Diabetes Therapy A new oral GLP-1 medication
Description
Time in range improved from 69.4% to 74.2%, daily insulin use fell by 11.3 units, and participants reduced carbohydrate intake and body weight with no increase in hypoglycemia
After the introductory period, ongoing fills run $299$349 per month
doi: 10.1111/dom.13741 53 MehrtashFDushayJMansonJE
Korner M, Stockli M, Waser B, Reubi JC (2007) GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting
